Compare · ATLN vs BIO
ATLN vs BIO
Side-by-side comparison of Atlantic International Corp. (ATLN) and Bio-Rad Laboratories Inc. (BIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATLN and BIO operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BIO is the larger of the two at $10.44B, about 142.6x ATLN ($73.2M).
- Over the past year, ATLN is down 80.6% and BIO is up 31.9% - BIO leads by 112.4 points.
- ATLN has been more active in the news (9 items in the past 4 weeks vs 2 for BIO).
- BIO has more recent analyst coverage (12 ratings vs 0 for ATLN).
- Company
- Atlantic International Corp.
- Bio-Rad Laboratories Inc.
- Price
- $0.90-5.48%
- $390.39+2.45%
- Market cap
- $73.2M
- $10.44B
- 1M return
- -38.55%
- +23.48%
- 1Y return
- -80.57%
- +31.87%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- 1980
- News (4w)
- 9
- 2
- Recent ratings
- 0
- 12
Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Latest ATLN
- Circle8 Group Delivers Record $569.7 Million First-Half Revenue, Up 177%
- SEC Form 10-Q filed by Atlantic International Corp.
- Amendment: Atlantic International Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- SEC Form NT 10-Q filed by Atlantic International Corp.
- Atlantic International Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- SEC Form 424B7 filed by Atlantic International Corp.
- Circle8 Ranked #1 in 2025 Dutch Public-Sector Broker/MSP Contract Awards, With Approximately US$2.39 Billion in Awarded Framework Value
- SPP Credit Advisors and Circle8 Group Eliminate $35 Million Convertible Seller's Note in Global Settlement Agreement
- Circle8 Group Eliminates $35 Million Convertible Seller's Note Through Definitive Settlement Agreement With SPP Credit Advisors
- Circle8 Awarded Two $20 Million Dutch Public Sector Contract Extensions, Demonstrating Positive Commercial Momentum Across the Public Sector
Latest BIO
- IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
- Bio-Rad Reports Second-Quarter 2026 Financial Results
- Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026
- RBC Capital Mkts resumed coverage on Bio-Rad Labs with a new price target
- Bio-Rad to Participate in Upcoming Investor Conferences
- Bio-Rad Reports First-Quarter 2026 Financial Results
- Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
- Bio-Rad Labs downgraded by Citigroup with a new price target
- Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
- Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026